Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study

NCT01735955 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

57

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Myelogenous Leukemia (CML)
Metastatic Gastrointestinal Stromal Tumors (GIST)
Acute Lymphoblastic Leukemia (ALL)
Receptor Tyrosine Kinase (KIT) Mutated Melanoma

Interventions

DRUG: Nilotinib

Sponsor

Novartis Pharmaceuticals